Philips’ New Acute Care Patient Monitoring Solutions for Hospital-Based Remote Monitoring Granted FDA Emergency Use Authorization

Royal Philips (Amsterdam, the Netherlands) has been granted Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) for its IntelliVue Patient Monitors MX750/MX850 and its IntelliVue Active Displays AD75/AD85, for use in the US during the COVID-19 health emergency.

Philips’ IntelliVue Patient Monitors MX750/MX850 and IntelliVue Active Displays AD75/AD85 received CE mark in 2019 and are already being used in hospitals across Europe. The EUA allows Philips to start delivering the new remote patient monitoring solution to hospitals in the US, and the company is committed to submitting a 510(k) to FDA for this acute care solution in the course of 2020.


Hospitals and health systems are increasingly relying on health technology to better manage the influx of COVID-19 patients they are seeing in Emergency Rooms (ERs) and Intensive Care Units (ICUs). To minimize staff exposure to the virus that causes COVID-19 while still delivering quality care, there is a critical need for patient monitors that enable clinicians to remotely monitor a patient’s condition.

The IntelliVue Patient Monitors MX750/MX850 and IntelliVue Active Displays AD75/AD85 offer advanced functionality and clinical decision support capabilities such as Philips’ IntelliVue Horizon Trends information view, which shows deviations in vital signs (for example, CO2 and heart rate) to contextualize a patient’s condition, while also supporting infection-control protocols and access to key information both remotely and at the bedside. Features such as Philips’ Alarm Advisor and Alarm Reporting help to reduce alarm fatigue for caregivers, while the smooth glass surfaces, rounded edges and special surface material of the monitors and displays facilitates cleaning and disinfection.

The MX750 and MX850 monitors are the latest additions to Philips’ portfolio of integrated patient monitoring solutions to support improved clinical and operational workflows. The MX750 and MX850 also include updated features, including enhancements to monitor and assess clinical and network device performance, and additional functionalities to strengthen cybersecurity.

“As the world continues to battle against COVID-19, we’re committed to ramping up production of all critical solutions that can help in this time of crisis,” said Peter Ziese, General Manager, Monitoring and Analytics at Philips. “This FDA EUA for our MX750 and MX850 monitors and IntelliVue AD75 and AD85 Active Displays allows us to do that for these remote patient monitoring solutions, which are of vital need in the ICU. At Philips, being able to provide the right information at the right time to caregivers has always been a top priority. Now more than ever, there’s an urgent need to make sure those on the frontline have all the available resources at their disposal.”